Skip to search formSkip to main contentSkip to account menu

Cytospora sp. 24 LY10

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Abstract 2366: Targeting PI3 pathway in ibrutinib resistant diffuse large B-cell lymphoma
Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma (NHL) and approximately 30% of patients… 
2015
2015
Suppression of CD300A inhibits the growth of diffuse large B-cell lymphoma
CD300A is a type I transmembrane receptor protein which has shown inhibitory effects on B-cell receptor-mediated signals. In an… 
2013
2013
Dual Targeting With The Selective Histone Deacetylase (HDAC) 6 Inhibitor, ACY-1215, and Bortezomib (BOR) Leads To Marked Disruption Of Protein Degradation Pathways and Apoptosis In Preclinical Models…
The development of isoform selective HDAC inhibitors has opened the opportunity to better define and target pathways germane to… 
Highly Cited
2011
Highly Cited
2011
Antitumor Activity of the Investigational Proteasome Inhibitor MLN9708 in Mouse Models of B-cell and Plasma Cell Malignancies
Purpose: The clinical success of the first-in-class proteasome inhibitor bortezomib (VELCADE) has validated the proteasome as a… 
2011
2011
Abstract 3590: The Bruton tyrosine kinase inhibitor PCI-32765 prevents activation of pro-survival NF-kB pathways in OCI-Ly10 ABC DLBCL cells
Proceedings: AACR 102nd Annual Meeting 2011‐‐ Apr 2‐6, 2011; Orlando, FL PCI-32765 is a potent and selective small molecule… 
Highly Cited
2005
Highly Cited
2005
c-Jun N-terminal kinase (JNK) is required for survival and proliferation of B-lymphoma cells.
Several primary murine and human B lymphomas and cell lines were found to constitutively express high levels of the activated… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)